Search Results

There are 5382 results for: content related to: Effects of short-term sitagliptin treatment on immune parameters in healthy individuals, a randomized placebo-controlled study

  1. Dipeptidyl peptidase-4 inhibitors: Multitarget drugs, not only antidiabetes drugs (D ipeptidyl peptidase -4抑制剂:多靶点药物,不仅仅是降糖药)

    Journal of Diabetes

    Volume 6, Issue 1, January 2014, Pages: 21–29, Yunjuan Zhao, Lin Yang and Zhiguang Zhou

    Version of Record online : 19 JUN 2013, DOI: 10.1111/1753-0407.12063

  2. You have free access to this content
    Dipeptidyl peptidase 4 promotes epithelial cell transformation and breast tumourigenesis via induction of PIN1 gene expression

    British Journal of Pharmacology

    Volume 172, Issue 21, November 2015, Pages: 5096–5109, H J Choi, J Y Kim, S-C Lim, G Kim, H J Yun and H S Choi

    Version of Record online : 16 OCT 2015, DOI: 10.1111/bph.13274

  3. You have free access to this content
    Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system

    Clinical & Experimental Immunology

    Volume 185, Issue 1, July 2016, Pages: 1–21, C. Klemann, L. Wagner, M. Stephan and S. von Hörsten

    Version of Record online : 13 MAY 2016, DOI: 10.1111/cei.12781

  4. Synthetic lethal interaction of combined CD26 and Bcl-xL inhibition is a powerful anticancer therapy against hepatocellular carcinoma

    Hepatology Research

    Volume 45, Issue 9, September 2015, Pages: 1023–1033, Tsukasa Kawaguchi, Takahiro Kodama, Hayato Hikita, Yuki Makino, Yoshinobu Saito, Satoshi Tanaka, Satoshi Shimizu, Ryotaro Sakamori, Takuya Miyagi, Hiroshi Wada, Hiroaki Nagano, Naoki Hiramatsu, Tomohide Tatsumi and Tetsuo Takehara

    Version of Record online : 12 NOV 2014, DOI: 10.1111/hepr.12434

  5. Sitagliptin and pioglitazone provide complementary effects on postprandial glucose and pancreatic islet cell function

    Diabetes, Obesity and Metabolism

    Volume 15, Issue 12, December 2013, Pages: 1101–1110, M. Alba, B. Ahrén, S. E. Inzucchi, Y. Guan, M. Mallick, L. Xu, E. A. O'Neill, D. E. Williams-Herman, K. D. Kaufman and B. J. Goldstein

    Version of Record online : 18 JUL 2013, DOI: 10.1111/dom.12145

  6. You have free access to this content
    Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial

    Diabetes, Obesity and Metabolism

    Volume 9, Issue 2, March 2007, Pages: 194–205, M. A. Nauck, G. Meininger, D. Sheng, L. Terranella, P. P. Stein and Sitagliptin Study 024 Group

    Version of Record online : 26 JAN 2007, DOI: 10.1111/j.1463-1326.2006.00704.x

  7. Longer term safety of dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes mellitus: systematic review and meta-analysis

    Diabetes, Obesity and Metabolism

    Volume 14, Issue 12, December 2012, Pages: 1061–1072, K. Gooßen and S. Gräber

    Version of Record online : 17 MAY 2012, DOI: 10.1111/j.1463-1326.2012.01610.x

  8. You have free access to this content
    Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure

    European Journal of Heart Failure

    Volume 14, Issue 1, January 2012, Pages: 14–21, Nelson Gomez, Karim Touihri, Veerle Matheeussen, Agnès Mendes Da Costa, Maryam Mahmoudabady, Myrielle Mathieu, Lesley Baerts, Aaron Peace, Pascale Lybaert, Simon Scharpé, Ingrid De Meester, Jozef Bartunek, Marc Vanderheyden and Kathleen McEntee

    Version of Record online : 18 FEB 2014, DOI: 10.1093/eurjhf/hfr146

  9. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes

    Diabetes, Obesity and Metabolism

    Volume 10, Issue 10, October 2008, Pages: 959–969, R. Scott, T. Loeys, M. J. Davies, S. S. Engel and for the Sitagliptin Study 801 Group

    Version of Record online : 14 JAN 2008, DOI: 10.1111/j.1463-1326.2007.00839.x

  10. Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug

    Diabetes, Obesity and Metabolism

    Volume 9, Issue 2, March 2007, Pages: 153–165, Iskandar Idris and Richard Donnelly

    Version of Record online : 31 JAN 2007, DOI: 10.1111/j.1463-1326.2007.00705.x

  11. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency

    Diabetes, Obesity and Metabolism

    Volume 10, Issue 7, July 2008, Pages: 545–555, J. C. N. Chan, R. Scott, J. C. Arjona Ferreira, D. Sheng, E. Gonzalez, M. J. Davies, P. P. Stein, K. D. Kaufman, J. M. Amatruda and D. Williams-Herman

    Version of Record online : 28 JUN 2008, DOI: 10.1111/j.1463-1326.2008.00914.x

  12. You have free access to this content
    Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes

    Diabetes, Obesity and Metabolism

    Volume 12, Issue 3, March 2010, Pages: 252–261, P. Aschner, H. L. Katzeff, H. Guo, S. Sunga, D. Williams-Herman, K. D. Kaufman, B. J. Goldstein and for the Sitagliptin Study 049 Group

    Version of Record online : 25 NOV 2009, DOI: 10.1111/j.1463-1326.2009.01187.x

  13. Combined treatment with a dipeptidyl peptidase-IV inhibitor (sitagliptin) and an angiotensin II type 1 receptor blocker (losartan) promotes islet regeneration via enhanced differentiation of pancreatic progenitor cells

    Diabetes, Obesity and Metabolism

    Volume 14, Issue 9, September 2012, Pages: 842–851, J. Liang, K. K. Leung, S. Y. Lam and P. S. Leung

    Version of Record online : 8 MAY 2012, DOI: 10.1111/j.1463-1326.2012.01612.x

  14. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus

    Intervention Review

    The Cochrane Library

    Bernd Richter, Elizabeth Bandeira-Echtler, Karla Bergerhoff and Christian Lerch

    Published Online : 23 APR 2008, DOI: 10.1002/14651858.CD006739.pub2

  15. You have free access to this content
    The dipeptidyl peptidase IV family in cancer and cell biology

    The FEBS Journal

    Volume 277, Issue 5, March 2010, Pages: 1126–1144, Denise M. T. Yu, Tsun-Wen Yao, Sumaiya Chowdhury, Naveed A. Nadvi, Brenna Osborne, W. Bret Church, Geoffrey W. McCaughan and Mark D. Gorrell

    Version of Record online : 13 JAN 2010, DOI: 10.1111/j.1742-4658.2009.07526.x

  16. Association of musculoskeletal complaints and gliptin use: review of spontaneous reports

    Pharmacoepidemiology and Drug Safety

    Volume 22, Issue 10, October 2013, Pages: 1115–1118, Mónica Tarapués, Gloria Cereza and Albert Figueras

    Version of Record online : 19 AUG 2013, DOI: 10.1002/pds.3503

  17. You have full text access to this OnlineOpen article
    Sitagliptin attenuates sympathetic innervation via modulating reactive oxygen species and interstitial adenosine in infarcted rat hearts

    Journal of Cellular and Molecular Medicine

    Volume 19, Issue 2, February 2015, Pages: 418–429, Tsung-Ming Lee, Wei-Ting Chen, Chen-Chia Yang, Shinn-Zong Lin and Nen-Chung Chang

    Version of Record online : 11 NOV 2014, DOI: 10.1111/jcmm.12465

  18. Effect of a Single Cyclosporine Dose on the Single-Dose Pharmacokinetics of Sitagliptin (MK-0431), a Dipeptidyl Peptidase-4 Inhibitor, in Healthy Male Subjects

    The Journal of Clinical Pharmacology

    Volume 47, Issue 2, February 2007, Pages: 165–174, Dr Rajesh Krishna, Dr Arthur Bergman, Dr Patrick Larson, Mr Josee Cote, Dr Kenneth Lasseter, Ms Stacey Dilzer, Dr Amy Wang, Dr Wei Zeng, Mr Li Chen, Dr John Wagner and Dr Gary Herman

    Version of Record online : 7 MAR 2013, DOI: 10.1177/0091270006296523

  19. You have free access to this content
    Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin

    Diabetes, Obesity and Metabolism

    Volume 9, Issue 5, September 2007, Pages: 733–745, K. Hermansen, M. Kipnes, E. Luo, D. Fanurik, H. Khatami, P. Stein and Sitagliptin Study 035 Group

    Version of Record online : 26 JUN 2007, DOI: 10.1111/j.1463-1326.2007.00744.x

  20. Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers

    Biopharmaceutics & Drug Disposition

    Volume 28, Issue 6, September 2007, Pages: 315–322, Arthur Bergman, David Ebel, Fang Liu, Julie Stone, Amy Wang, Wei Zeng, Li Chen, Stacy Dilzer, Kenneth Lasseter, Gary Herman, John Wagner and Rajesh Krishna

    Version of Record online : 18 JUN 2007, DOI: 10.1002/bdd.560